Publications
- Treatment options for non-small cell lung stage III cancer2021 | Third Faculty of Medicine, Faculty of Medicine in Pilsen
- Efficacy of erlotinib in subsequent lines of non-small cell lung cancer therapy2018 | Third Faculty of Medicine
- Pleural mesothelioma2023 | Third Faculty of Medicine
- ALK-positive advanced non-small cell lung cancer patient with poor performance status - case report2023 | Third Faculty of Medicine
- Amivantamab in non‐small cell lung cancer treatment2023 | Third Faculty of Medicine
- Worse Prognosis in the Symptomatic Patients With Lung Cancer - Czech Multicentric Study2022 | Third Faculty of Medicine, Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer2022 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Second Faculty of Medicine
- Laboratory Parameters Associated with Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer2022 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Second Faculty of Medicine
- Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer2022 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Second Faculty of Medicine
- First-line treatment for non-squamous NSCLC without driver mutations2022 | Third Faculty of Medicine
Loading network view...